Houston, TX, (July 27, 2004) Cytogenix, Inc. ((CYGX: OTC: BB))
CytoGenix, Inc. (CYGX: OTC: BB) announced today that it has filed new patent applications for Nucleotides for Prevention and Treatment of Bacterial and Fungal Pathologies under the Patent Cooperation Treaty (PCT) of the World Intellectual Property Organization (WIPO).
The Company has also filed for protection for the invention titled Intracellular Generation of Single-stranded DNA under national phase PCT filings in twelve countries including France, Germany, Switzerland, China, India and Israel, and the Company received a publication date for the PCT application filed for the invention titled Treatment of HSV-Related Pathologies Using ssDNA.
Malcolm Skolnick, President and CEO of CytoGenix stated, "We continue to aggressively pursue the discovery of novel therapeutic compounds based on our ssDNA technology and protecting our intellectual property. Going forward, we expect to maintain a pace of eight to ten new filings a year."
CytoGenix, Inc. is a biopharmaceutical company that develops and markets innovative products and services based on its proprietary DNA expression technology. CytoGenix has products in pre-clinical development including, anti-herpes, anti-psoriasis and anti-inflammatory topical creams. The company owns a US patent for its core DNA expression technology and has 40 international or US pending patent applications.
SAFE HARBOR: Except for statements of historical fact, the statements in this press release are forward-looking. Such statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include, but are not limited to, general economic conditions, risks associated with the acceptance of new products, competition, and other factors more fully detailed in the company's filings with the Securities and Exchange Commission. Additional information about CytoGenix and its technology can be found on the website at www.cytogenix.com.
Contact: Communications Director — Juan Ferreira, (407) 774-9949
